Chemin Messidor 5-7
Case Postale 5911
CH - 1002
192 articles with Debiopharm
9/24/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Debiopharm Honored as a 2020 Swiss Biotech Success Story Winner For Outstanding Achievements Over 40 Years
Debiopharm, ( www.debiopharm.com ), a Swiss-based biopharmaceutical company today announced being one of the recipients of the 2020 Swiss Biotech Success Story Award for exceptional achievements in the biotech industry. Every year, the Swiss Biotech Association awards companies or individuals within the biotech sector i
Debiopharm's New Generation Radionuclide Therapy Advances Into Clinical Research In The Fight Against Lung Cancer
First patient dosed in the phase I small cell lung cancer (SCLC) trial with Debio 1124, a molecular-targeted radiotherapy
Debiopharm's IAP Antagonist Significantly Improves Overall Survival of High-Risk Head & Neck Cancer Patients
Promising overall survival outcomes at 3-years for high-risk, locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) patients observed with Debio 1143 + CRT
Debiopharm's Novel Microbiome Remodeling Program Licensed to Takeda for the Treatment of Gastrointestinal Disorders
Takeda will pursue the development of a novel preclinical narrow spectrum microbiome remodeling program, to treat diseases related to dysbiosis of the human gut microbiome
Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer
Debiopharm and Verity Pharmaceuticals Inc. announced having entered into an exclusive agreement that grants Verity Pharmaceuticals Inc., in the United States of America, the rights to commercialize Trelstar® a hormone therapy for patients living with prostate cancer.
Acquisition of Debiopharm's Investment Portfolio Company Kaiku Health Broadens Patient Access to Digital Oncology Intervention
Debiopharm announces successful exit deal for Kaiku Health, a Finnish start-up specializing in digital solutions for improved patient outcomes and experience
Debiopharm Expands Its Radiopharmaceutical Footprint with an Exclusive In-Licensing Agreement of 3B Pharmaceutical's Targeted CAIX Radiotherapy
Debiopharm, a Swiss-based biopharmaceutical company, announced today having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program, now called Debio 0228, which targets the CAIX (Carbonic Anh
Debiopharm ( www.debiopharm.com ), a Swiss biopharmaceutical company, announced today the advancement of their phase 1 study.
FDA Grants Breakthrough Therapy Designation for Debiopharm's Novel Chemo-Radio Sensitizer Debio 1143 for Front-line Treatment of Head & Neck Cancer
Debiopharm announced that the American Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for Debio 1143, the most clinically advanced IAP antagonist, for the treatment of patients with confirmed diagnosis
Carevive Systems raises new financing round with Philips and Debiopharm to accelerate advances in cancer care delivery
NORTH MIAMI, Fla. , Feb. 13, 2020 /PRNewswire/ -- Carevive Systems, a leading oncology-focused health technology company, announced today that it has received Series C funding from new investors Philips Health Technology Ventures and Debiopharm Innovation Fund, and existing investors Cerner Capital, HLM Venture Partners, LRVHealth, and Co-Founder/CEO Madelyn Trupkin Herzfeld
Knight Therapeutics Inc., a pan-American specialty pharmaceutical company and Debiopharm, a Swiss-based, global biopharmaceutical company, announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® in Canada.
Debiopharm Progresses in Their Stand Against Drug-resistant N. Gonorrhoeae with Extended CARB-X Funding of Their Debio 1453 Antibiotic Program
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today it has been awarded the 2nd phase funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to continue the development of its antibiotic program Debio 1453, leading to a novel FabI inhibitor drug candidate specifically targeting Neisseria gonorrhoeae
A Pancreatic and Colorectal Cancer Trial Initiated to Address the Needs of Patients With Immune Checkpoint Inhibitor (ICI)-Resistant Disease by Combining Debiopharm's Debio 1143 IAP Antagonist With Keytruda®
First patient enrolled in the investigator initiated CATRIPCA study at the Léon Bérard Cancer Center in Lyon, France
Debiopharm's Novel IAP Antagonist Debio 1143 Achieves Outstanding Phase II Results for High-Risk Head and Neck Cancer Patients
Late breaking abstract results presented today at ESMO with chemo-radio sensitizer Debio 1143 present a promising breakthrough strategy to improve the front-line treatment of H&N cancer patients
BC Platforms Provides Complete Data Management Solution for Debiopharm’s Oncology Development Portfolio
BC Platforms announced that it has formed a collaboration with Debiopharm, a Swiss pharmaceutical company, to deliver a complete clinical and genomic data management solution to support its innovative oncology pipeline, including investigational product programs for Debio 0123, diagnostic molecular screening for Debio 1347 and clinical exploratory results for Debio 1143.
Debiopharm Successfully Completes Randomized Phase II Study For IAP Antagonist Debio 1143 in High Risk Head & Neck Cancer Patients
This robust Phase II trial, which included 96 patients, was designed to demonstrate the efficacy and safety of this IAP antagonist, first in its class to be Phase III ready.
Debiopharm and Ipsen Extend Their Strategic Decapeptyl® (triptorelin) Partnership for Another 15 Years
Debiopharm and Ipsen extend and strengthen their ongoing collaboration to ensure patient access to Decapeptyl® for the treatment of certain urological, gynecological and pediatric conditions
Debiopharm Expands its Immuno-Oncology Development Program for Debio 1143, with the First IAP Inhibitor/Nivolumab Combination Trial
First patient enrolled in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors
Debiopharm Awarded $2.1 Million From CARB-X in the Fight Against a Highly Resistant Nosocomial-Pneumonia Causing Superbug
The grant will support development of the Debio 1454 program to treat hospital-acquired pneumonia (HAP) caused by Acinetobacter baumannii